- Home
- OGEN vs EVOK Comparison
OGEN vs EVOK Comparison
Compare OGEN & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- EVOK
- Stock Information
- Founded
- OGEN 1996
- EVOK 2007
- Country
- OGEN United States
- EVOK United States
- Employees
- OGEN N/A
- EVOK N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- EVOK Health Care
- Exchange
- OGEN Nasdaq
- EVOK Nasdaq
- Market Cap
- OGEN 4.6M
- EVOK 4.2M
- IPO Year
- OGEN N/A
- EVOK 2013
- Fundamental
- Price
- OGEN $4.28
- EVOK $2.95
- Analyst Decision
- OGEN
- EVOK
- Analyst Count
- OGEN 0
- EVOK 0
- Target Price
- OGEN N/A
- EVOK N/A
- AVG Volume (30 Days)
- OGEN 599.0K
- EVOK 14.3K
- Earning Date
- OGEN 05-09-2025
- EVOK 05-13-2025
- Dividend Yield
- OGEN N/A
- EVOK N/A
- EPS Growth
- OGEN N/A
- EVOK N/A
- EPS
- OGEN N/A
- EVOK N/A
- Revenue
- OGEN N/A
- EVOK $11,594,083.00
- Revenue This Year
- OGEN N/A
- EVOK $57.82
- Revenue Next Year
- OGEN N/A
- EVOK $59.12
- P/E Ratio
- OGEN N/A
- EVOK N/A
- Revenue Growth
- OGEN N/A
- EVOK 89.89
- 52 Week Low
- OGEN $3.12
- EVOK $1.94
- 52 Week High
- OGEN $75.60
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- OGEN 43.10
- EVOK 38.86
- Support Level
- OGEN $3.12
- EVOK $3.33
- Resistance Level
- OGEN $9.60
- EVOK $3.66
- Average True Range (ATR)
- OGEN 1.04
- EVOK 0.29
- MACD
- OGEN -0.12
- EVOK -0.06
- Stochastic Oscillator
- OGEN 17.90
- EVOK 2.99
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.